Columbus-based startup DNA Nanobots has secured $3.5 million in fresh investment to innovate gene therapy delivery systems without relying on viruses. Utilizing “DNA origami,” the company engineers self-assembling structures that transport therapeutic payloads directly to diseased cells, bypassing the immune system. This funding, part of a $5 million Seed round, extends their operational runway by 18 months, allowing for advancements in pre-clinical studies, manufacturing, and strategic hiring. CEO Jim Lynch expressed gratitude for investor support, emphasizing the potential to achieve key milestones by 2026. The company, a spinout from The Ohio State University, highlights the growth of Ohio’s life sciences sector. With $1.5 million still needed to complete the Seed round, DNA Nanobots aims to advance to IND-enabling studies, a crucial step before first-in-human clinical trials.
How is DNA Nanobots transforming gene therapy with $3.5 million funding?
